Skip to main navigation
  • Back to SpringWorksTx.com
  • Investors & Media
  • Contact Us
  • Linkedin
  • Twitter
SpringWorks
  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
  • Corporate Governance
  • Financial Information
    • SEC Filings
    • Annual Reports
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Investor Resources
    • Investor FAQs
    • Investor Contacts
    • Email Alerts
  • Investors + Media
  • Medical Professionals
  • Contact Us
  • Linkedin
  • Twitter

Press Releases

07 Nov 2018
SpringWorks Therapeutics Receives FDA Fast Track Designation for Nirogacestat for the Treatment of Adult Patients with Desmoid Tumors
PDF Version
05 Nov 2018
SpringWorks Therapeutics Receives FDA Orphan Drug Designation for MEK Inhibitor (PD-0325901) for the Treatment of Neurofibromatosis Type 1
PDF Version
06 Sep 2018
BeiGene and SpringWorks Therapeutics Enter into Global Clinical Collaboration to Evaluate Targeted Combination Therapy in Advanced Solid Tumors
PDF Version
05 Sep 2018
SpringWorks Therapeutics Announces Appointment of Saqib Islam as Chief Executive Officer
PDF Version
05 Mar 2018
SpringWorks Therapeutics to Present at Cowen and Company’s 38th Annual Health Care Conference
PDF Version
05 Jan 2018
SpringWorks Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference
PDF Version
25 Sep 2017
SpringWorks Therapeutics Launches with $103M in Series A Funding and Rights to Four Clinical Programs
PDF Version

Pagination

  • First page « first
  • Previous page ‹ previous
  • …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Current page 11
Displaying 101 - 107 of 107

Springworks - Toolkits

  • Print Page
  • Email Alerts
  • RSS Feeds
  • Investor Contacts

Springworks Logo

Social Links

  • linkedin
  • twitter
Footer 1
  • Who We Are
    • Leadership & Board
    • Mission & Values
    • Partners & Collaborators
  • Focus Areas
    • Rare Oncology
    • BCMA Combinations in Multiple Myeloma
    • Biomarker-Defined Metastatic Solid Tumors
Footer 2
  • Pipeline
    • Nirogacestat
    • Mirdametinib
    • Clinical Trials
    • Investigator-Initiated Research
  • Careers
    • View Opportunities
    • Desmoid Tumor Commercial Team
Footer 3
  • Patients
    • Desmoid Tumors
    • NF1-PN
    • Expanded Access
  • Contact
Footer 4
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Stock Information
    • Investor Resources

© 2023 SpringWorks Therapeutics. All rights reserved.

Copyright Links

  • Privacy Policy
  • Terms of Use
  • Cookie Policy